Discordant effects of Janus kinases inhibition ex-vivo on inflammatory responses in colonic compared to ileal mucosa.
Kawsar KaboubHanan Abu-TahaJessica ArrouasseEfrat Shaham-BardaNir WasserbergLucille Hayman-ManzurAdi FriedenbergAdva Levy-BardaIdan GorenZohar LeviHagar Banai-EranIrit Avni-BironJacob E OllechTali Sharar-FischlerHenit YanaiSarit Cohen-KedarIris DotanKeren M RabinowitzPublished in: Journal of Crohn's & colitis (2024)
Site-specific anti-inflammatory effect of JAK inhibition by tofacitinib was noticed, whereby the colon was more robustly affected than the ileum. Ex-vivo response to tofacitinib is individual. JAK inhibition may attenuate inflammation by decreasing iNOS expression. Ex-vivo mucosal platforms may be a valuable resource for studying personalized drug effects in patients with IBD.